Barclays sets GBp 1,800.00 target for GSK stock

Published on 10/27/2026 at 17:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK's Q2 revenue reached GBP 8.41 billion in its report. GSK stock costs EUR 22.91 on October 27, 2026, up 0.35 percent versus the Xetra close.

Barclays target and GSK results

Barclays maintained a Sell rating and set a GBp 1,800.00 target on October 27, 2026.
GSK reported GBP 8.41 billion in second-quarter revenue and GBP 435.00 million in net profit.
GSK stock costs EUR 22.91 at Lang & Schwarz on October 27, 2026 at 5:03 p.m. CET, 0.35 percent above the Xetra close of October 26, 2026.

GSK, GB00BN7SWP63, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) faced a fresh bearish analyst signal on October 27, 2026, when Barclays maintained a Sell rating and set a GBp 1,800.00 price target, according to Markets Insider. GSK was trading at EUR 22.91 at Lang & Schwarz on October 27, 2026 at 5:03 p.m. CET, up 0.35 percent versus the Xetra close of October 26, 2026 at EUR 22.83.

What does the rating add?

The Barclays call contrasts with the Buy stance that Jefferies maintained earlier in October, leaving investors with a wide range of views on the pharmaceutical group. The latest target also sits below the level used by Jefferies, which retained a GBp 2,500.00 target in its October 21 research note, according to Yahoo Finance.

Revenue reached GBP 8.41 billion

GSK's second-quarter revenue was GBP 8.41 billion and net profit was GBP 435.00 million, compared with GBP 7.99 billion in revenue and GBP 1.44 billion in net profit a year earlier. The figures make the earnings mix important: revenue increased, while profit was lower against the prior-year comparison. These reported results were cited by Markets Insider.

Stock stays below its yearly high

The EUR 22.91 quote stands 11.95 percent below the 52-week high of EUR 26.02 and above the 52-week low of EUR 18.49. GSK's market capitalization was EUR 75.9 billion, while its 2026 performance was up 7.52 percent in the quoted German market data. The London-listed company is also preparing its next reporting event.

Results date and valuation

GSK's investor-relations page states that third-quarter 2026 results are scheduled for October 28, 2026, one day after this report. The company is listed on the London Stock Exchange and belongs to the FTSE 100. Its portfolio spans vaccines, specialty medicines and general medicines, with HIV treatments among its major commercial areas.

Stock position after the analyst call

The price reaction remains limited against the Xetra close, so the Barclays rating is the more distinctive valuation signal for the session. The contrasting GBp 1,800.00 and GBp 2,500.00 targets underline the range of broker expectations ahead of the results date.

GSK stock was trading at EUR 22.91 at Lang & Schwarz on October 27, 2026 at 5:03 p.m. CET, 0.35 percent above the Xetra close of October 26, 2026 at EUR 22.83.

The further course of trading is shown by the continuously updated real-time quote of GSK stock.